Aim: To evaluate the impact on overall survival (OS) of gastrectomy in asymptomatic metastatic esophago-gastric cancer. Patients & methods: Five hundred and thirteen patients were included. The role of surgery and other clinico-pathological factors was evaluated by univariate and Cox regression analyses. OS was the primary end point. Results: Multivariate analysis confirmed that gastrectomy was a predictor of longer OS (p < 0.001), as well as preserved performance status and benefit from first-line chemotherapy. None of the investigated clinico-pathological variables identified preferable candidates for surgery (all p > 0.05). Conclusion: Palliative gastrectomy might play a role in asymptomatic metastatic esophago-gastric cancer patients with good performance status who received benefit from first-line chemotherapy. Future prospective trials integrating tumor biology among inclusion criteria may help defining the optimal candidates.
Selecting patients for gastrectomy in metastatic esophago-gastric cancer : clinics and pathology are not enough / L. Fornaro, V. Fanotto, G. Musettini, M. Uccello, L. Rimassa, C. Vivaldi, C. Fontanella, F. Leone, R. Giampieri, G. Rosati, M. Lencioni, D. Santini, S.D. Donato, G. Tomasello, O. Brunetti, F. Pietrantonio, F. Bergamo, M. Scartozzi, A. Avallone, S.E. Lutrino, D. Melisi, L. Antonuzzo, A. Pellegrino, L. Gerratana, S. Cordio, E. Vasile, G. Aprile. - In: FUTURE ONCOLOGY. - ISSN 1479-6694. - 13:25(2017 Oct), pp. 2265-2275. [10.2217/fon-2017-0246]
Selecting patients for gastrectomy in metastatic esophago-gastric cancer : clinics and pathology are not enough
F. Pietrantonio;
2017
Abstract
Aim: To evaluate the impact on overall survival (OS) of gastrectomy in asymptomatic metastatic esophago-gastric cancer. Patients & methods: Five hundred and thirteen patients were included. The role of surgery and other clinico-pathological factors was evaluated by univariate and Cox regression analyses. OS was the primary end point. Results: Multivariate analysis confirmed that gastrectomy was a predictor of longer OS (p < 0.001), as well as preserved performance status and benefit from first-line chemotherapy. None of the investigated clinico-pathological variables identified preferable candidates for surgery (all p > 0.05). Conclusion: Palliative gastrectomy might play a role in asymptomatic metastatic esophago-gastric cancer patients with good performance status who received benefit from first-line chemotherapy. Future prospective trials integrating tumor biology among inclusion criteria may help defining the optimal candidates.File | Dimensione | Formato | |
---|---|---|---|
20170715-fornaro-Futureoncol.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
1.29 MB
Formato
Adobe PDF
|
1.29 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.